Corium International, Inc. (CORI) Analysts See $-0.39 EPS

July 11, 2018 - By Christine McCrea

Investors sentiment decreased to 1.32 in Q1 2018. Its down 0.47, from 1.79 in 2017Q4. It is negative, as 7 investors sold Corium International, Inc. shares while 18 reduced holdings. 14 funds opened positions while 19 raised stakes. 32.85 million shares or 6.87% more from 30.74 million shares in 2017Q4 were reported.
Citigroup invested 0% of its portfolio in Corium International, Inc. (NASDAQ:CORI). 3,127 are owned by Tower Cap Lc (Trc). Veritable Limited Partnership holds 40,600 shares. Ny State Common Retirement Fund has 0% invested in Corium International, Inc. (NASDAQ:CORI) for 21,200 shares. State Street Corp owns 0% invested in Corium International, Inc. (NASDAQ:CORI) for 373,743 shares. Wells Fargo And Mn stated it has 43,174 shares or 0% of all its holdings. Iguana Health Limited Liability holds 0.83% or 110,000 shares in its portfolio. Citadel Limited holds 39,708 shares. Rhumbline Advisers has invested 0% of its portfolio in Corium International, Inc. (NASDAQ:CORI). Renaissance Technology Ltd Company holds 0% in Corium International, Inc. (NASDAQ:CORI) or 96,700 shares. Moreover, Kazazian Asset Mgmt Llc has 0.23% invested in Corium International, Inc. (NASDAQ:CORI). Proshare Ltd Liability Corporation holds 0% of its portfolio in Corium International, Inc. (NASDAQ:CORI) for 19,303 shares. Victory Cap Management Incorporated has 0% invested in Corium International, Inc. (NASDAQ:CORI). Opaleye Management holds 1.07M shares or 3.49% of its portfolio. The New York-based Awm Invest Inc has invested 5.02% in Corium International, Inc. (NASDAQ:CORI).

Analysts expect Corium International, Inc. (NASDAQ:CORI) to report $-0.39 EPS on August, 2.They anticipate $0.04 EPS change or 9.30 % from last quarter’s $-0.43 EPS. After having $-0.50 EPS previously, Corium International, Inc.’s analysts see -22.00 % EPS growth. The stock increased 3.12% or $0.24 during the last trading session, reaching $7.94. About 186,325 shares traded. Corium International, Inc. (NASDAQ:CORI) has risen 23.07% since July 12, 2017 and is uptrending. It has outperformed by 10.50% the S&P500.

Corium International, Inc. (NASDAQ:CORI) Ratings Coverage

Among 2 analysts covering Corium (NASDAQ:CORI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corium had 7 analyst reports since February 9, 2018 according to SRatingsIntel. Cantor Fitzgerald maintained it with “Buy” rating and $1400 target in Tuesday, March 27 report. The firm has “Buy” rating given on Tuesday, May 15 by H.C. Wainwright. The rating was maintained by Cantor Fitzgerald on Monday, May 14 with “Buy”. On Friday, February 9 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Cantor Fitzgerald maintained Corium International, Inc. (NASDAQ:CORI) rating on Thursday, March 8. Cantor Fitzgerald has “Buy” rating and $14.0 target. H.C. Wainwright maintained Corium International, Inc. (NASDAQ:CORI) rating on Friday, February 9. H.C. Wainwright has “Buy” rating and $14.0 target. The firm earned “Buy” rating on Friday, June 15 by H.C. Wainwright.

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. The company has market cap of $287.77 million. It offers Clonidine Transdermal Delivery System , a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. It currently has negative earnings. The company??s products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease.

More important recent Corium International, Inc. (NASDAQ:CORI) news were published by: Investingnews.com which released: “Corium Announces Issuance of Key US Patent Covering Corplex Donepezil Transdermal System for Alzheimer’s Disease” on June 13, 2018, also Nasdaq.com published article titled: “Corium Announces Issuance of Additional US Patent Covering Corplexâ„¢ Donepezil Transdermal System for …”, Seekingalpha.com published: “An Update On Corium International” on June 15, 2018. More interesting news about Corium International, Inc. (NASDAQ:CORI) was released by: Globenewswire.com and their article: “Corium Announces Issuance of Key US Patent Covering Corplexâ„¢ Donepezil Transdermal System for Alzheimer’s …” with publication date: June 13, 2018.

Corium International, Inc. (NASDAQ:CORI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.